category,datetime,headline,id,image,related,source,summary,url
company,1768057200,Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer,138069119,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,"NEW YORK, January 10, 2026--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. At the time of this analysis, the BRAFTOVI combination regimen with FOLFIRI and cetuximab dem",https://finnhub.io/api/news?id=6ea8eb3a7792171edff218ebcf16bf708d439ce97ce483a16b44ca24f26d59b1
company,1768039200,AstraZeneca: Oncology Dominance Justifies New All-Time Highs,138056039,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357662733/image_1357662733.jpg?io=getty-c-w1536,PFE,SeekingAlpha,AstraZeneca hit a 2026 high on strong oncology/cardiovascular sales.,https://finnhub.io/api/news?id=37fedf41221f724240bb6e5a39b561db6df5999f1666745993872e232235f2b3
company,1768032730,Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed,138069120,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,"Madrigal Pharmaceuticals recently announced an exclusive global license agreement with Pfizer for ervogastat, an oral DGAT-2 inhibitor targeting MASH, with more details shared at the 44th Annual J.P. Morgan Healthcare Conference on January 9, 2026. At the same time, a downgrade from Wolfe Research on valuation and competitive grounds has sharpened investor focus on the durability and breadth of Madrigal’s MASH franchise. We’ll now examine how Wolfe Research’s valuation downgrade, alongside...",https://finnhub.io/api/news?id=2ccc454296ac2a8a6ff735e4173a36ac52d60e690feb0ef93e872c5f528d804a
company,1768032001,2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market,138057241,https://image.cnbcfm.com/api/v1/image/108231152-17640105232025-11-24t185245z_617754530_rc263iabxpyr_rtrmadp_0_novo-nordisk.jpeg?v=1764010568&w=1920&h=1080,PFE,CNBC,"Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year. ",https://finnhub.io/api/news?id=0ef44fbf4b4de83c0e82bc17f6a38c818f9abb8935eb227d5b1980953b744477
